Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomized controlled trials. Lancet Diabetes Endocrinol 5:431–437 Article PubMed Google Scholar Turnbull FM, Abraira C, Anderson RJ et al (2009) ...
interest/arousal disorder (FSIAD). However, it is noted that the majority of clinical trials discussed in this paper used the DSM IV-R diagnoses of HSDD and FSAD. The authors concluded that medications in early phase trials showed promise for the treatment of FSD. These therapies focus on tr...
Recent studies have explored the impact of histone deacetylase inhibitors (HDACi) on cancer, with several HDACi being tested in clinical trials. We previously showed that HDACi, such as SAHA, can induce cell death in acute myeloid leukemia (AML) cells by reactivating the TRAIL gene. This tumo...
clinical trialsnormal agingThe O -methyltransferase, which is responsible for the methylation of farnesoic acid in the corpora allata of Diploptera punctata , is a cytosolic enzyme. The activity of O -methyltransferase closely parallels JH biosynthesis in last instars and adult females. Because ...
While existing remedies failed to fully address the consequences of heart failure, stem cell therapy has been introduced as a promising approach. The present review is a comprehensive appraisal of the impacts of using mesenchymal stem cells (MSCs) in clinical trials mainly conducted on ischemic cardi...
21,37 Although the inhibition of GA progression has historically been used as a clinical end point in investigational trials of therapeutic agents, it has consistently been proven to be a challenging target to achieve.38 Although we now have complement inhibitor agents to slow GA progression, to ...
Moreover, while the study identifies promising therapeutic targets, further research is needed to evaluate the efficacy of targeting OAS genes in clinical trials to confirm their therapeutic potential and applicability in personalized medicine. Conclusion This study examined the role of the OAS gene ...
which may not fully capture the complexity of in vivo conditions. Moreover, while the study identifies promising therapeutic targets, further research is needed to evaluate the efficacy of targeting OAS genes in clinical trials to confirm their therapeutic potential and applicability in personalized medi...
The treatment exposure duration is specified on ClinicalTrials.gov; the recruitment period is calculated as the total trial duration minus the treatment study period. The Common Alzheimer's Disease Research Ontology (CADRO) of the National Institute on Aging and the Alzheimer's Association; the ...
clinical trials and preclinical studies that have used nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), apolipoprotein E2 (APOE2), and human telomerase reverse transcriptase (hTERT) as therapeutic gene therapy approaches. These gene targets have shown potential to alleviate the ...